Risk Score of Zwart et al for Triple Antithrombotic Therapy in a Patient with Atrial Fibrillation Who Undergoes Percutaneous Coronary Intervention (PCI)
Zwart et al reported a score that can identify a patient with atrial fibrillation who may benefit from triple antithrombotic therapy following percutaneous coronary intervention (PCI). The authors are from multiple institutions in Europe and the United States.
Patient selection: atrial fibrillation and percutaneous coronary intervention (PCI)
Parameters:
(1) left ventricular ejection fraction (LVEF) in percent
(2) 3-vessel coronary artery disease
(3) myocardial infarction (AMI) as indication for index PCI
(4) history of peripheral artery disease (PAD)
(5) platelet count in 10^9/L
(6) eGFR in mL/min
Parameter
Finding
Points
LVEF
> 50%
0
30 to 50%
1
< 30%
3
3-vessel disease
no
0
yes
2
AMI as indication
no
0
yes
2
history of PAD
no
0
yes
2
platelet count
< 400* 10^9/L
0
>= 400 * 10^9/L
3
eGFR
>= 90 mL/min
-1
< 90 mL/min
0
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: -1
• maximum score: 12
• A score >= 5 indicates a clinical benefit from triple antithrombotic drug therapy.
To read more or access our algorithms and calculators, please log in or register.
